JAZZ Stock Analysis: Jazz Pharmaceuticals | NASDAQ

Sleep Disorders, Epilepsy, Oncology, Rare Diseases

Total Rating 65

Safety 75

Buy Signal 0.56

Biotechnology
Industry Rotation: -16.6

Market Cap: 16.4B
Avg Turnover: 180M

Risk 3d forecast

Volatility30.4%

VaR 5^th Pctl4.97%

VaR vs Median-0.77%

Reward TTM

Sharpe Ratio2.33

Rel. Str. IBD93.9

Rel. Str. Peer Group78.1

Character TTM

Beta0.556

Beta Downside-0.009

Hurst Exponent0.553

Drawdowns 3y

Max DD32.71%

CAGR/Max DD0.70

CAGR/Mean DD1.62

EPS (Earnings per Share)

EPS CAGR: -14.52%
EPS Trend: -29.9%

Last SUE: -0.10
Qual. Beats: 0

Revenue

Rev. CAGR: 6.57%
Rev. Trend: 96.4%

Last SUE: 1.94
Qual. Beats: 2

Warnings

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.6 years of data

Jan -0.1% 7

Feb +0.6% 5

Mar +3.4% 20

Apr +2.0% 5

May -1.8% 10

Jun -0.8% 8

Jul +0.2% 19

Aug -1.4% 11

Sep -1.4% 28

Oct +0.0% 2

Nov -0.7% 11

Dec +0.1% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Dublin, Ireland-headquartered specialty biopharmaceutical company founded in 2003 that identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and other international markets. Listed on NASDAQ since June 2007, the company sits within the Health Care sector and, as a Large Cap (approximately $14B market capitalization), operates with a business model centered on specialty drug development, regulatory exclusivity, and commercialization in rare and serious disease areas.

Its marketed product portfolio is diversified across neurology (Xywav for cataplexy/EDS in narcolepsy and idiopathic hypersomnia; Epidiolex for seizures associated with LGS, Dravet syndrome, and tuberous sclerosis complex), oncology (Rylaze and Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma; Zepzelca for metastatic small cell lung cancer; Ziihera for HER2-positive biliary tract cancers; Modeyso for H3 K27M-mutant diffuse midline glioma; Vyxeos for certain AML indications), and hematology (Defitelio for severe veno-occlusive disease).

Jazz maintains a development pipeline spanning Phase 1 through Phase 3 trials, including Zanidatamab (HER2-positive gastroesophageal adenocarcinoma and biliary tract cancers), Dordaviprone (H3 K27M-mutant diffuse glioma), expanded Vyxeos indications, JZP3507 for pheochromocytoma/paraganglioma, and earlier-stage programs such as JZP815, JZP898, and JZP047. The company supplements its internal research through licensing and collaboration agreements with partners including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.

Headlines to Watch Out For

Xywav revenue growth offsets Xyrem generic competition pressure
Epidiolex and Zepzelca sales expand rare disease oncology portfolio
Acquisition debt burden limits buyback and capital allocation flexibility

Piotroski VR-10 (Strict) 6.0

Net Income: 940.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.14 > 0.02 and ΔFCF/TA 2.36 > 1.0
NWC/Revenue: 37.76% < 20% (prev 31.30%; Δ 6.46% < -1%)
CFO/TA 0.15 > 3% & CFO 1.66b > Net Income 940.8m
Net Debt (2.27b) to EBITDA (1.48b): 1.54 < 3
Current Ratio: 1.78 > 1.5 & < 3
Outstanding Shares: last quarter (69.4m) vs 12m ago 13.41% < -2%
Gross Margin: 84.67% > 18% (prev 88.71%; Δ -4.04% > 0.5%)
Asset Turnover: 41.78% > 50% (prev 37.34%; Δ 4.44% > 0%)
Interest Coverage Ratio: 4.74 > 6 (EBIT TTM 921.9m / Interest Expense TTM 194.4m)

Altman Z'' 2.73

A: 0.16 (Total Current Assets 3.97b - Total Current Liabilities 2.23b) / Total Assets 11.1b
B: 0.10 (Retained Earnings 1.13b / Total Assets 11.1b)
C: 0.08 (EBIT TTM 921.9m / Avg Total Assets 11.0b)
D: 0.76 (Book Value of Equity 4.80b / Total Liabilities 6.28b)
Altman-Z'' = 2.73 = A

Beneish M -2.87

DSRI: 1.10 (Receivables 880.9m/714.0m, Revenue 4.60b/4.09b)
GMI: 1.05 (GM 88.71% / 84.67%)
AQI: 0.92 (AQ_t 0.62 / AQ_t-1 0.67)
SGI: 1.13 (Revenue 4.60b / 4.09b)
TATA: -0.07 (NI 940.8m - CFO 1.66b) / TA 11.1b)
Beneish M = -2.87 (Cap -4..+1) = A

What is the price of JAZZ shares?

As of August 09, 2026, the stock is trading at USD 256.56 with a total of 673,173 shares traded. Over the past week, the price has changed by +1.46%, over one month by +3.57%, over three months by +13.04% and over the past year by +128.91%.

Current recommended Stop Loss: 239.70 (which is 6.6% or 2.2 ATR below the current price).

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.

StrongBuy: 10
Buy: 6
Hold: 2
Sell: 0
StrongSell: 0

What are the forecasts/targets for the JAZZ price?

Analysts Target Price	266.9	4%

Jazz Pharmaceuticals (JAZZ) - Fundamental Data Overview as of 06 August 2026

Market Cap USD = 16.4b (16.4b USD * 1.0 USD.USD)
P/E Trailing = 2616.2
P/E Forward = 10.7991
P/S = 3.6909
P/B = 3.5046
P/EG = 0.9582
Revenue TTM = 4.60b USD
EBIT TTM = 921.9m USD
EBITDA TTM = 1.48b USD
Long Term Debt = 4.33b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 4.47b USD (from shortLongTermDebtTotal, last quarter) + Leases 62.2m
Net Debt = 2.27b USD (calculated: Debt 4.47b - CCE 2.20b)
Enterprise Value = 18.7b USD (16.4b + Debt 4.47b - CCE 2.20b)
Interest Coverage Ratio = 4.74 (Ebit TTM 921.9m / Interest Expense TTM 194.4m)
EV/FCF = 12.13x (Enterprise Value 18.7b / FCF TTM 1.54b)
FCF Yield = 8.25% (FCF TTM 1.54b / Enterprise Value 18.7b)
FCF Margin = 33.52% (FCF TTM 1.54b / Revenue TTM 4.60b)
Net Margin = 20.45% (Net Income TTM 940.8m / Revenue TTM 4.60b)
Gross Margin = 84.67% ((Revenue TTM 4.60b - Cost of Revenue TTM 705.2m) / Revenue TTM)
Gross Margin QoQ = 90.37% (prev 71.34%)
Tobins Q-Ratio = 1.69 (Enterprise Value 18.7b / Total Assets 11.1b)
Interest Expense / Debt = 4.35% (Interest Expense 194.4m / Debt 4.47b)
Taxrate = 8.58% (18.1m / 211.0m)
NOPAT = 842.8m (EBIT 921.9m * (1 - 8.58%))
Current Ratio = 1.78 (Total Current Assets 3.97b / Total Current Liabilities 2.23b)
Debt / Equity = 0.93 (Debt 4.47b / totalStockholderEquity, last quarter 4.80b)
Debt / EBITDA = 1.54 (Net Debt 2.27b / EBITDA 1.48b)
Debt / FCF = 1.47 (Net Debt 2.27b / FCF TTM 1.54b)
Total Stockholder Equity = 4.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.54% (Net Income 940.8m / Total Assets 11.1b)
RoE = 21.37% (Net Income TTM 940.8m / Total Stockholder Equity 4.40b)
RoCE = 10.56% (EBIT 921.9m / Capital Employed (Equity 4.40b + L.T.Debt 4.33b))
RoIC = 8.73% (NOPAT 842.8m / Invested Capital 9.65b)
WACC = 7.09% (E(16.4b)/V(20.9b) * Re(7.94%) + D(4.47b)/V(20.9b) * Rd(4.35%) * (1-Tc(0.09)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 14.31 | Cagr: 4.74%
[DCF] Terminal Value 77.97% ; FCFF base≈1.43b ; Y1≈1.64b ; Y5≈2.41b
[DCF] Fair Price = 542.4 (EV 36.3b - Net Debt 2.27b = Equity 34.1b / Shares 62.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -29.92 | EPS CAGR: -14.52% | SUE: -0.10 | # QB: 0
Revenue Correlation: 96.36 | Revenue CAGR: 6.57% | SUE: 1.94 | # QB: 2
EPS current Quarter (2026-09-30): EPS=6.37 | Chg30d=-0.23% | Revisions=-10% | Analysts=17
EPS current Year (2026-12-31): EPS=25.31 | Chg30d=-0.32% | Revisions=-22% | GrowthEPS=+202.0% | GrowthRev=+5.7%
EPS next Year (2027-12-31): EPS=25.72 | Chg30d=+0.44% | Revisions=-29% | GrowthEPS=+1.6% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: -25% (up=6, down=11)